CA-DIGITATE
27.10.2021 15:02:05 CEST | Business Wire | Press release
Digitate , a SaaS-based, leading provider of autonomous enterprise solutions, today announced its recognition as a market and category leader in AIOps by multiple leading analyst firms and industry reports. Digitate earned these merits as a result of its high customer ratings and wide breadth of solutions that span across IT and business operations, as well as assurance.
Digitate’s flagship product ignio™ is an end-to-end autonomous solution that uses advanced machine learning and AI capabilities to bring contextual intelligence to IT operations. ignio™ enables enterprises with a one-of-a-kind closed-loop solution that combines context, insights and intelligent automation to autonomously predict, prevent and prescribe for issues. Digitate is helping Fortune 500 companies harness the power of AI and automation as they scale to meet the demands of their own customers and ease the ever-increasing workload on IT teams.
"Our growth over the past few years speaks to the strength of our solutions in supporting our customers' goals for digital transformation success,” said Akhilesh Tripathi, CEO of Digitate. “Digitate is committed to providing customers an AI-driven, closed-loop platform that further improves productivity, business continuity, and customer experience. Our recognition as a market leader by several prominent analyst and industry reports is a validation of our investments and the adoption of our solutions across some of the world’s leading enterprises”
Digitate’s success is highlighted by several notable achievements and recognition in 2021, including:
- Named a leader in the Omdia “AIOps Universe – Selecting an AIOps Solution 2021 - 2022” Report – Due in part to its strong automation capabilities and management control, Digitate was recognized for its commitment to creating value for business functions through automation and comprehensive AIOps capabilities. Digitate was the leader in the overall customer experience with a recommendation score of 96%. To support Digitate’s all-rounder status, it scored 95% for solution breadth.
- Recognized on the Constellation Research ShortList™ for Using Artificial Intelligence in IT Operations (AIOps) Q3 2021 – Constellation’s list evaluated over 40 most prominent AIOps solutions based on client inquiries, partner conversations, customer references, vendor selection projects, market share and internal research. Digitate was selected based on its noise reduction and enterprise capabilities, among other criteria.
- Recognized as a technology leader in Quadrant Knowledge Solution’s SPARKS Matrix for Artificial Intelligence for IT Operations (AIOps) Platform 2021 Report –The report pointed out some of the key differentiators that include Digitate’s over 10 000 out-of-the-box automation capabilities and unique, closed-loop system ensuring better ROI and lower time to value.
- Highlighted in the IDC Worldwide IT Operations Analytics Software Market Shares Report – Digitate was the second fastest-growing IT Operations Analytics software company for 2020, with a revenue growth rate of 43.5%. (August 2021, IDC #US48125121)
- Highlighted in the IDC Worldwide Workload Management Software Market Shares Report – Digitate was the fastest growing WLM software company for 2020 with a revenue growth rate of 75.6 %. (July 2021, IDC #US48063321)
About Digitate
Digitate is a leading software provider bringing agility, assurance, and resiliency to IT and business operations. Digitate’s flagship product ignio™ is an award-winning AIOps software that reimagines enterprise IT and business landscape with its unique and innovative closed-loop approach by combining context, insights and intelligent automation to autonomously resolve and prevent issues. Our customers span across industry verticals and include large, global enterprises that are leaders and innovators in their respective industries. Digitate is headquartered in Santa Clara, California, USA and Pune, India. To stay up to date on ignio™ news and to learn more how our clients across the globe have benefited from our innovative solutions: Visit us at www.digitate.com , and follow Digitate on Twitter and LinkedIn .
Learn more about our AIOps solution here: http://www.youtube.com/watch?v=xy3FGkbZNDM
View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005225/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 18:27:00 CET | Press release
His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom